147 related articles for article (PubMed ID: 34242938)
1. A physiologically based pharmacokinetic/pharmacodynamic modeling approach for drug-drug interaction evaluation of warfarin enantiomers with sorafenib.
Wang Z; Xiang X; Liu S; Tang Z; Sun H; Parvez M; Ghim JL; Shin JG; Cai W
Drug Metab Pharmacokinet; 2021 Aug; 39():100362. PubMed ID: 34242938
[TBL] [Abstract][Full Text] [Related]
2. Prediction of the impact of
Asari K; Takahashi H
Pharmacogenomics; 2020 Aug; 21(12):853-862. PubMed ID: 32700644
[No Abstract] [Full Text] [Related]
3. A physiologically-based pharmacokinetic/pharmacodynamic modeling approach for drug-drug-gene interaction evaluation of S-warfarin with fluconazole.
Geng K; Shen C; Wang X; Wang X; Shao W; Wang W; Chen T; Sun H; Xie H
CPT Pharmacometrics Syst Pharmacol; 2024 May; 13(5):853-869. PubMed ID: 38487942
[TBL] [Abstract][Full Text] [Related]
4. A Physiological-Based Pharmacokinetic Model Embedded with a Target-Mediated Drug Disposition Mechanism Can Characterize Single-Dose Warfarin Pharmacokinetic Profiles in Subjects with Various
Cheng S; Flora DR; Rettie AE; Brundage RC; Tracy TS
Drug Metab Dispos; 2023 Feb; 51(2):257-267. PubMed ID: 36379708
[TBL] [Abstract][Full Text] [Related]
5. [Population pharmacokinetic/pharmacodynamic modeling of warfarin by nonlinear mixed effects model].
Lin RF; Lin WW; Wang CL; Huang PF; Fang SJ
Yao Xue Xue Bao; 2015 Oct; 50(10):1280-4. PubMed ID: 26837174
[TBL] [Abstract][Full Text] [Related]
6. New insights into the role of VKORC1 polymorphisms for optimal warfarin dose selection in Caribbean Hispanic patients through an external validation of a population PK/PD model.
Rodríguez-Fernández K; Reynaldo-Fernández G; Reyes-González S; de Las Barreras C; Rodríguez-Vera L; Vlaar C; Monbaliu JM; Stelzer T; Duconge J; Mangas-Sanjuan V
Biomed Pharmacother; 2024 Jan; 170():115977. PubMed ID: 38056237
[TBL] [Abstract][Full Text] [Related]
7. Prediction of sensitivity to warfarin based on VKORC1 and CYP2C9 polymorphisms in patients from different places in Colombia.
Cifuentes RA; Murillo-Rojas J; Avella-Vargas E
Biomedica; 2016 Mar; 36(1):91-100. PubMed ID: 27622442
[TBL] [Abstract][Full Text] [Related]
8. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
[TBL] [Abstract][Full Text] [Related]
9. Impact of CYP2C9-Interacting Drugs on Warfarin Pharmacogenomics.
Agrawal S; Heiss MS; Fenter RB; Abramova TV; Perera MA; Pacheco JA; Smith ME; Rasmussen-Torvik LJ; George AL
Clin Transl Sci; 2020 Sep; 13(5):941-949. PubMed ID: 32270628
[TBL] [Abstract][Full Text] [Related]
10. Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients.
Natarajan S; Ponde CK; Rajani RM; Jijina F; Gursahani R; Dhairyawan PP; Ashavaid TF
Pharmacol Rep; 2013; 65(5):1375-82. PubMed ID: 24399734
[TBL] [Abstract][Full Text] [Related]
11. Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.
Chen W; Wu L; Liu X; Shen Y; Liang Y; Zhu J; Tan H; Yang Y; Liu Q; Wang M; Liu L; Wang X
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):126-132. PubMed ID: 27117036
[TBL] [Abstract][Full Text] [Related]
12. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
[TBL] [Abstract][Full Text] [Related]
13. Proposal of a prediction model describing the metabolic interaction between warfarin and sorafenib using a population pharmacokinetic approach.
Asari K; Takahashi H
Int J Clin Pharmacol Ther; 2021 Mar; 59(3):202-215. PubMed ID: 33191909
[TBL] [Abstract][Full Text] [Related]
14. Genotyping of CYP2C9 and VKORC1 polymorphisms predicts south Indian patients with deep vein thrombosis as fast metabolizers of warfarin/acenocoumarin.
Arunkumar G; Vishnuprabu D; Nupur B; Vidyasagaran T; Murugan AK; Munirajan AK
Drug Discov Ther; 2017; 11(4):198-205. PubMed ID: 28867752
[TBL] [Abstract][Full Text] [Related]
15. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
Ghozlan MF; Foad DA; Darwish YW; Saad AA
Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611
[TBL] [Abstract][Full Text] [Related]
16. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
Miao L; Yang J; Huang C; Shen Z
Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
Beinema M; Brouwers JR; Schalekamp T; Wilffert B
Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
[TBL] [Abstract][Full Text] [Related]
18. Effect of VKORC1 and CYP2C9 polymorphisms on warfarin dose requirement in Bangladeshi population.
Chowdhury ZS; Shahjin F; Akter F; Ahmed M; Islam MS; Bin Sayeed MS; Islam R; Hasnat A
Pak J Pharm Sci; 2017 Mar; 30(2):341-346. PubMed ID: 28649054
[TBL] [Abstract][Full Text] [Related]
19. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.
An SH; Chang BC; Lee KE; Gwak HS
Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945
[TBL] [Abstract][Full Text] [Related]
20. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
